Barclays Cuts Twist Bioscience (NASDAQ:TWST) Price Target to $45.00

Twist Bioscience (NASDAQ:TWST) had its target price decreased by Barclays from $58.00 to $45.00 in a research note published on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other equities research analysts have also weighed in on TWST. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a report on Friday, March 28th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Twist Bioscience Price Performance

TWST opened at $38.85 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The stock’s 50 day simple moving average is $41.83 and its 200 day simple moving average is $44.66. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -11.49 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same period in the prior year, the business posted ($0.75) EPS. The firm’s revenue was up 24.1% compared to the same quarter last year. As a group, analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares of the company’s stock, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 1,259 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the transaction, the senior vice president now directly owns 132,014 shares of the company’s stock, valued at approximately $6,514,890.90. This trade represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,796 shares of company stock worth $1,077,383 in the last three months. 3.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after buying an additional 189,791 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares during the period. State Street Corp lifted its stake in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock valued at $63,895,000 after purchasing an additional 6,908 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.